NCT05064436View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis

PHASE1TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 10, 2021

Primary Completion Date

December 18, 2023

Study Completion Date

December 18, 2023

Conditions
Multiple Sclerosis (MS)
Interventions
DRUG

11C-BMS-986196

Specified dose on specified days

Trial Locations (2)

48109

Local Institution - 0001, Ann Arbor

W12 0HS

Local Institution - 0002, London

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05064436 - A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis | Biotech Hunter | Biotech Hunter